Immunovant, Inc.
IMVT
$15.08
$0.191.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.16% | 34.84% | 30.98% | 22.22% | 17.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.81% | 62.15% | 59.79% | 43.24% | 27.64% |
| Operating Income | -57.81% | -62.15% | -59.79% | -43.24% | -27.64% |
| Income Before Tax | -63.88% | -59.58% | -56.56% | -26.35% | -11.03% |
| Income Tax Expenses | 163.51% | 56.97% | 182.16% | 273.29% | 285.03% |
| Earnings from Continuing Operations | -64.12% | -59.58% | -57.20% | -26.54% | -11.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.12% | -59.58% | -57.20% | -26.54% | -11.46% |
| EBIT | -57.81% | -62.15% | -59.79% | -43.24% | -27.64% |
| EBITDA | -57.81% | -62.15% | -59.80% | -43.24% | -27.64% |
| EPS Basic | -48.37% | -44.94% | -43.10% | -12.80% | 0.52% |
| Normalized Basic EPS | -48.21% | -52.74% | -50.38% | -23.54% | -8.88% |
| EPS Diluted | -48.37% | -44.94% | -43.10% | -12.80% | 0.52% |
| Normalized Diluted EPS | -48.21% | -52.74% | -50.38% | -23.54% | -8.88% |
| Average Basic Shares Outstanding | 11.26% | 9.91% | 9.15% | 12.04% | 12.24% |
| Average Diluted Shares Outstanding | 11.26% | 9.91% | 9.15% | 12.04% | 12.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |